Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.

Familial cancer - 1 Apr 2017

Nilsson Martin P, Winter Christof, Kristoffersson Ulf, Rehn Martin, Larsson Christer, Saal Lao H, Loman Niklas

Abstract excerpt

Increasing evidence supports the benefit of identifying BRCA1 and BRCA2 germline mutations in early breast cancer. Selection of patients for genetic testing is based on defined criteria taking individual and family history related factors into account. It is important to make a distinction between efficacy and effectiveness of BRCA testing criteria. Efficacy can be defined as the performance under ideal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Early Detection of Cancer

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Testing

Share to Germ-Line Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 28120249
DOI: 10.1007/s10689-016-9953-x
PMCID: PMC5357494

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.PMID 28120249Read ↗

Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families.Semantic proximity Read ↗

BRCA testing and outcomes in women with breast cancer.Semantic proximity Read ↗

Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.Semantic proximity Read ↗

Prevalence, prognosis, and health care resource utilization in carriers of pathogenic germline variants in BRCA1/2 with incident early-stage breast cancer: a Finnish population-based study.Semantic proximity Read ↗

BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.Semantic proximity Read ↗

Decision aids for female BRCA mutation carriers: a scoping review.Semantic proximity Read ↗

Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.Semantic proximity Read ↗

Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.Semantic proximity Read ↗

Mainstreamed Genetic Testing of Breast Cancer Patients in Two Hospitals in South Eastern NorwaySemantic proximity Read ↗

BRCA1/2 testing: uptake, phenocopies, and strategies to improve detection rates in initially negative families.Semantic proximity Read ↗

Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.Semantic proximity Read ↗

Development of a scoring system to screen for BRCA1/2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.